Pharsight

Actonel generic

Actonel is an osteoporotic treatment drug owned by Apil. Launched on March 27, 1998, it contains the active ingredient risedronate sodium. Over the course of its lifespan, 4 patents have been filed for Actonel, all of which have now expired.

When will Actonel generic be available?

As all patents for Actonel have expired, the release of Actonel generics is possible. The last patent, US7718634*PED, expired on November 6, 2023. Therefore, the earliest possible release date for the generic version was right after this date.

Actonel uses

Actonel is primarily used for the treatment and prevention of osteoporosis, particularly in postmenopausal women. Its active ingredient, risedronate sodium, helps by slowing bone loss to increase bone mass and decrease the likelihood of fractures.

Actonel patent expiration

Actonel has had a total of 4 patents, all of which have now expired. The last patent, US7718634*PED, expired on November 6, 2023. Accordingly, the prospect for Actonel generics became possible right after this date. Below are the details of the patent:

EPO Oppostions filed on Actonel

Actonel dosage

Want to ask something?